Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.
Arch Endocrinol Metab
; 65(2): 242-247, 2021 Nov 01.
Article
in English
| MEDLINE | ID: covidwho-1080888
ABSTRACT
Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for treatment when conventional therapeutics approaches are not effective, a frequent situation in the majority of patients. We present our experience in the management of a patient with unresectable anaplastic thyroid cancer who had a remarkable and rapid response to treatment with dabrafenib and trametinib during the COVID-19 pandemic. After four weeks of dabrafenib 150 mg twice daily plus trametinib 2 mg daily, he showed a dramatic reduction of the cervical mass around 90%. Nearly eight weeks under treatment with dabrafenib plus trametinib, the patient remains with minimal locoregional disease without distant metastases.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thyroid Neoplasms
/
Thyroid Carcinoma, Anaplastic
/
COVID-19
Type of study:
Case report
/
Prognostic study
Limits:
Humans
/
Male
Language:
English
Journal:
Arch Endocrinol Metab
Year:
2021
Document Type:
Article
Affiliation country:
2359-3997000000325
Similar
MEDLINE
...
LILACS
LIS